Pharma and tech companies including Amazon Inc., Astrazeneca plc, Pfizer Inc., Merck & Co. Inc. and Teva Inc. are partnering with an innovation lab based in Israel to accelerate artificial intelligence (AI) driven antibody discovery. Rehovot, Israel-based Aion Labs recently launched a venture hub for innovators and scientists from around the world.
Following the termination of a planned merger with SPAC Medtech Acquisition Corp., Tel Aviv-based Memic Innovative Surgery Ltd. is looking to slowly roll out its Hominis surgical platform. Nasdaq-listed SPAC Medtech and Memic called off the agreement due to “market volatility and world events.”
As the American Urological Association (AUA) annual meeting prepares to kick off on May 12, newly published prostate cancer guidelines recommend two tests to help clinicians and patients determine the best path forward for treatment—or waiting. The latest AUA guidelines incorporated Exact Sciences Corp.’s Oncotype DX Genomic Prostate Score (GPS) test for risk-stratification of localized prostate cancer, while the National Comprehensive Cancer Network (NCCN) added Cleveland Diagnostics Inc.’s Isopsa test to help identify high-grade early prostate cancer before a biopsy or after a negative biopsy result.
Ten years from now, what medical technologies will generate the most economic value and where is the industry heading? At the annual Biomed Israel conference, held in Tel Aviv, health care, pharmaceutical and technology advisor, and board director Sandra Morgan examined research from consulting firm McKinsey & Co. and beyond on the biggest innovation trends in the sector.
At the annual Biomed Israel conference, held in Tel Aviv, Eyal Lifschitz, co-founder of Israeli venture capital fund Peregrine Venture, urged entrepreneurs to adapt their business strategy or face a long, difficult road to exit. With strategic companies increasingly favoring companies later in development, Lifschitz advised innovators to expand their vision beyond the traditional buyers.
Cybersecurity remains a pressing issue for medical technology, in part because there are new, small companies jumping into this space seemingly every day. However, there is a shortage of talent in cybersecurity, something that Dan Lyon, director of cybersecurity at Boston Scientific Corp., of Marlborough, Mass., said will not ease soon due to a lack of interest among colleges and universities in providing curriculum and degrees in this area.
In response to the COVID-19 pandemic, health systems around the world are looking to digital technologies to support health delivery but where exactly can these technologies have the most impact? At the Medtech Forum in Barcelona, European leaders gathered to discuss practical examples of how digital tools can help make health systems more efficient.
The attempt by the U.S. FDA to harmonize its Quality System Regulation (QSR) with ISO 13485 promises to be a difficult slog, but Jeff Shuren, director of the agency’s device center, said the agency is flexible on the proposed one-year implementation deadline. However, Shuren also noted that the draft rule would not be converted into a final rule at any point during the current calendar year, leaving device makers with an extended term of uncertainty.
As was the case with left atrial appendage closure, renal denervation (RD) as a treatment for hypertension has proven to be difficult to move along into routine clinical usage. New data for a study sponsored by Medtronic plc showed that RD offers a statistically significant improvement over sham treatment in reducing hypertension, but the data do not seem to suggest that patients will be able to drop their antihypertensive medications after RD treatment.
The tricuspid valve at times seems the lost child of the heart’s valves, but new research hints that regurgitation of this valve can be resolved with a transcatheter replacement. Adam Greenbaum, of Emory University School of Medicine, said the early feasibility study of the Pascal valve by Edwards Lifesciences Inc., of Irvine, Calif., demonstrated a large improvement in mortality at one year and significant improvements in heart failure status, a result that offers new hope for these patients.